A carregar...
Minimal Residual Disease Status as a Surrogate Endpoint for Progression-Free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis
BACKGROUND: Therapeutic advances have greatly extended survival times in patients with multiple myeloma, necessitating increasingly lengthy trials when using survival outcomes primary endpoints. A surrogate endpoint that can more rapidly predict survival could accelerate drug development. We conduct...
Na minha lista:
| Publicado no: | Clin Lymphoma Myeloma Leuk |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7444731/ https://ncbi.nlm.nih.gov/pubmed/31780415 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2019.09.622 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|